Clinical Trial Update: A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 [Phase 3]

View source ↗

Summary

A 26-week randomized, double-blind, double-dummy Phase 3 trial evaluating the efficacy and safety of QVA149 in chronic obstructive pulmonary disease has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-03-17